Abstract Details

Title Post-Hoc Analysis of Early AD Subjects Meeting Phase 3 Entry Criteria in PRIME, a Phase 1b Study of the Anti-Amyloid Beta Antibody Aducanumab (BIIB037)

Topic Aging, Dementia, and Behavioral Neurology

Presentation(s) (-)

Poster/Presentation
Number 007

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Vissia Viglietta, MD PRESENTER	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Yan Ling	No disclosure on file
Jeffrey J. Sevigny, MD (F. Hoffmann-La Roche)	Dr. Sevigny has received personal compensation for serving as an employee of Rapport Therapeutics.

��ɫ��

��ɫ��

Abstract Details

��ɫ����

��ɫ����

��ɫ��

��ɫ��